Zachary Brennan Senior Editor The FDA last week signed off on a safety-related change to the label of Biogen’s controversial Alzheimer’s drug Aduhelm, which has barely mustered any sales since its approval because payers have refused to cover it. The new label makes clear that physicians should, “Inform patients that events of intracerebral hemorrhage greater...